• Profile
Close

Effect of methylphenidate on apathy in patients with Alzheimer disease: The ADMET 2 randomized clinical trial

JAMA Oct 01, 2021

Mintzer J, Lanctôt KL, Scherer RW, et al. - Methylphenidate was compared with placebo in lowering the severity of apathy in individuals with Alzheimer disease.

  • A randomized clinical trial of 200 participants.

  • Relative to placebo, methylphenidate appeared safe and was linked with a reduction in apathy symptoms as assessed by the Neuropsychiatric Inventory within 2 months that was sustained for 6 months.

  • Overall, in individuals with Alzheimer disease, apathy can be managed by using methylphenidate, which in turn can decrease symptoms and caregiver burden. .

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay